Abstract The present study was designed to evaluate functional potential of Aloe vera juice against (CCl4 induced) hepatotoxicity using animal model. Biochemical analyses including liver, renal enzymes, bone biomarkers and lipid profile were conducted after 4 weeks of oral Aloe vera juice administration. Liver enzymes, AST, ALP and total bilirubin were reduced up to 15-7%, 60-32.52% and 29-48%, respectively in Aloe vera juice treated rats i.e., 10 mL/kg and 20 mL/kg doses. Reduction in serum cholesterol (8%), LDL (12%) and triglycerides (15%) were observed. Urea was significantly reduced up to 11% which further reduced up to 30% at higher dose. Increased content of serum proteins (23-50%) and albumin (40-116%) were found at the different doses. Vitamin D was found maximum in G4 i.e., 38.63 mg/dL as compared to lowest i.e., 5.12 mg/dL in G2, similarly improvement in calcium i.e., 11-22% was observed in G3 and G4. The serum oxidative stress markers indicated raised superoxide dismutase (9%), glutathione (15%), catalase (9%) and reduced lipid peroxidation 78% at higher concentration of Aloe vera juice consumption. In addition, histological evaluation also depicted positive impact on hepatic and renal portfolio in all treated rats. All of the findings enlighten the potential of Aloe vera juice as a functional beverage.

RESUMO Racional: O bypass gástrico em Y-de-Roux (RYGB) tem sido o procedimento bariátrico de escolha para pacientes com refluxo sintomático - e é conhecido por ser eficaz na redução da necessidade de medicação anti-refluxo no pós-operatório. No entanto, um pequeno número de pacientes com RYGB ainda pode desenvolver sintomas de refluxo graves que requerem uma intervenção cirúrgica. Objetivo: Examinar e descrever a população de pacientes que requer procedimento anti-refluxo após RYGB avaliando dados demográficos, características, sintomas e diagnóstico. Métodos: Revisão retrospectiva de prontuários foi realizada em 32 pacientes submetidos a hérnia hiatal e / ou fundoplicatura Nissen após RYGB em 1º de julho de 2014 a 31 de dezembro de 2019. Os pacientes foram identificados por meio do banco de dados MBSAQIP e seus prontuários eletrônicos foram revisados. Resultados: A maioria dos pacientes era do sexo feminino (n = 29 - 90,6%). A média de idade foi de 52,8 anos e o índice de massa corporea (IMC) médio de 34,1 kg / m2 na época do procedimento anti-refluxo. Os pacientes foram submetidos ao procedimento anti-refluxo em média 7,9 anos após o procedimento do BGYR. A porcentagem média de perda do excesso de IMC durante o tempo entre o BGYR e o procedimento anti-refluxo foi de 63,4%. Conclusões: Pacientes do sexo feminino com perda de peso significativa podem desenvolver sintomas graves de refluxo anos após o BGYR. Sintomas de refluxo após RYGB não devem ser negligenciadas. Acompanhamento cuidadoso e tratamento adequado (incluindo intervenção cirúrgica) são necessários para essa população.

ABSTRACT Background: Roux-en-Y gastric bypass (RYGB) has been the choice of bariatric procedure for patients with symptomatic reflux - and is known to be effective in reducing the need for anti-reflux medication postoperatively. However, a small number of RYGB patients can still develop severe reflux symptoms that require a surgical intervention. Aim: To examine and describe the patient population that requires an anti-reflux procedure after RYGB evaluating demographics, characteristics, symptoms and diagnosis Methods: A retrospective chart review was performed on 32 patients who underwent a hiatal hernia repair and/or Nissen fundoplication after RYGB Jul 1st, 2014 and Dec 31st, 2019. Patients were identified using the MBSAQIP database and their electronic medical records were reviewed. Results: Most patients were female (n=29, 90.6%). The mean age was 52.8 years and the mean body mass index (BMI) was 34.1 kg/m2 at the time of anti-reflux procedure. Patients underwent the anti-reflux procedure at a mean of 7.9 years after the RYGB procedure. The mean percentage of excess BMI loss during the time between RYGB and anti-reflux procedure was 63.4%. Conclusions: Female patients with a significant weight loss may develop a severe reflux symptoms years after RYGB. Complaints of reflux after RYGB should not be overlooked. Careful follow-up and appropriate treatment (including surgical intervention) is needed for this population.

RESUMO Racional: Anastomose única em bypass duodenoileal com gastrectomia vertical (SADI-S) foi introduzida na cirurgia bariátrica por Sanchez-Pernaute et al. como um avanço da derivação biliopancreática com switch duodenal. Objetivo: Avaliar o procedimento SADI-S no que diz respeito à perda de peso, resolução de comorbidades e taxa de complicações na população de superobesos. Métodos: Estudo retrospectivo com 72 pacientes iniciais que foram submetidos à laparoscopia ou por robô-assistida SADI-S laparoscópica entre 17 de dezembro de 2013 e 29 de Julho de 2015. Resultados: Foram incluídos 48 pacientes do sexo feminino e 21 do masculino com média idade de 42,4±10,0 anos (variação, 22-67). O índice de massa corporal (IMC) no momento do procedimento foi de 58,4±8,3 kg/m2 (42,3-91,8). O tempo médio de permanência hospitalar foi de 4,3±2,6 dias (3-24). A taxa de readmissão em 30 dias foi de 4,3% (n=3), devido à taquicardia (n=1), trombose venosa profunda (n=1), e gastroenterite viral (n=1). A taxa de reoperação em 30 dias foi de 5,8% (n=4) para a perfuração do intestino delgado (n=1), fístula (n=1), deiscência do coto duodenal (n=1), e laparoscopia de diagnóstico (n=1). Percentagem de excesso de perda de peso (% PEP) foi de 28,5±8,8% (13,3-45,0) em três meses (n=28), 41,7±11,1% (19,6-69,6) em seis meses (n=50), e 61,6±12,0% (40,1-91,2) aos 12 meses (n=23) após o procedimento. Um total de 18 pacientes (26,1%) apresentou-se com diabete melito tipo 2, no momento da operação. Desses, nove (50,0%) tiveram seu diabete resolvido, e seis (33,3%) tinham melhorado em 6-12 meses após SADI-S. Conclusões: SADI-S é operação viável com promissora perda de peso e de resolução do diabete melito na população de superobesos.

ABSTRACT Background: Single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) was introduced into bariatric surgery by Sanchez-Pernaute et al. as an advancement of the biliopancreatic diversion with duodenal switch. Aim: To evaluate the SADI-S procedure with regard to weight loss, comorbidity resolution, and complication rate in the super obese population. Methods: A retrospective chart review was performed on initial 72 patients who underwent laparoscopic or robot-assisted laparoscopic SADI-S between December 17th, 2013 and July 29th, 2015. Results: A total of 48 female and 21 male patients were included with a mean age of 42.4±10.0 years (range, 22-67). The mean body mass index (BMI) at the time of procedure was 58.4±8.3 kg/m2 (range, 42.3-91.8). Mean length of hospital stay was 4.3±2.6 days (range, 3-24). Thirty-day readmission rate was 4.3% (n=3), due to tachycardia (n=1), deep venous thrombosis (n=1), and viral gastroenteritis (n=1). Thirty-day reoperation rate was 5.8% (n=4) for perforation of the small bowel (n=1), leakage (n=1), duodenal stump leakage (n=1), and diagnostic laparoscopy (n=1). Percentage of excess weight loss (%EWL) was 28.5±8.8 % (range, 13.3-45.0) at three months (n=28), 41.7±11.1 % (range, 19.6-69.6) at six months (n=50), and 61.6±12.0 % (range, 40.1-91.2) at 12 months (n=23) after the procedure. A total of 18 patients (26.1%) presented with type II diabetes mellitus at the time of surgery. Of these patients, 9 (50.0%) had their diabetes resolved, and six (33.3%) had it improved by 6-12 months after SADI-S. Conclusions: SADI-S is a feasible operation with a promising weight loss and diabetes resolution in the super-obese population.